杭州百诚医药科技股份有限公司（以下简称“百诚医药”）于今日在深圳证券交易所创业板上市，募集资金约21.53亿元。海润天睿律师事务所在该IPO中担任发行人律师。

百诚医药成立于2011年，是一家以药学研究为核心的综合性医药技术研发企业，主要为各类制药企业、医药研发投资企业提供药物研发服务及研发技术成果转化。

海润天睿团队由高级合伙人、深圳分所主任唐申秋律师牵头，并由合伙人侯为满、林敏睿两位律师承办。

国金证券在该IPO中担任保荐人。

Hai Run acts on BIO-S’s IPO in Shenzhen’s GEM

Hai Run Law Firm has advised BIO-S, a Hangzhou-headquartered pharmaceutical technology enterprise, on its $340 million IPO in Shenzhen Stock Exchange’s GEM.

Established in 2011, BIO-S is a comprehensive enterprise focused on pharmaceutical technology research and development, providing drug R&D services for all types of drug maker and pharmaceutical R&D investor.

The Hai Run team was led by senior partner and the head of Shenzhen office Tang Shenqiu, who was supported by partners Hou Weiman and Lin Minrui.

Sinolink Securities acted as the issuer’s sponsor in this project.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.